ChemPartner, a China-based global contract research organisation (CRO) serving the biopharmaceutical industry, announced on Thursday the introduction of an updated visual identity and improved digital experience.
According to ChemPartner, this evolution clarifies its visual and verbal expression to better reflect its collaborative spirit and scalable expertise.
ChemPartner's refreshed digital experience at chempartner.com is designed to offer intuitive navigation to end-to-end capabilities, from discovery chemistry and biologics to DMPK and CMC. The site highlights real-world case studies, data and scientists behind the work, enabling visitors to easily explore and connect ChemPartner's expertise to their research goals.
RedHill advances RHB-102 across GI indications
Halozyme licenses ENHANZE to Skye Bioscience for nimacimab obesity programme
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
GSK secures China approval for Nucala in COPD
Insilico Medicine signs multi-year research and development collaboration with Servier
WuXi Biologics achieves ISO 20400 Sustainable Procurement certification
ChemPartner updates its visual identity and digital experience
Delcath publishes Phase 3 FOCUS subgroup data supporting HEPZATO in metastatic uveal melanoma
Axsome Therapeutics secures FDA priority review for AXS-05 in Alzheimer's disease agitation
Vanda's NEREUS approved by US FDA for prevention of motion sickness
HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China
SOFIE Biosciences reports first patient dosed Phase 3 clinical trial of [18F]FAPI-74